Research Square · 2021 · 16 citations · 9 references
Veterinary MedicineInfectious DiseasesMaternal HealthImmunizationVaccinologyWomen's HealthClinical Vaccine TrialsMaternal ImmunizationMrna Vaccine TechnologyVaccinationVaccine EffectivenessVaccine EfficacyCovid-19 Vaccination In PregnancyImmunogenicity In Pregnant WomenMass Immunization CampaignsPhase Iii Clinical TrialsPhase Iii Vaccine TrialsPregnancy Vaccine TrialsVaccination During PregnancyVaccine Effectiveness In Pregnancy
Abstract Background: As mass vaccination campaigns against COVID-19 accelerate worldwide, there remains only limited evidence regarding vaccine effectiveness (VE) among pregnant women. Pregnant women have been shown to be at risk for severe COVID-19, resulting in adverse obstetrics outcomes, and their immune system is known to undergo alterations during pregnancy. Phase III clinical trials of the approved mRNA COVID-19 vaccines excluded pregnant women, yet current guidelines encourage offering the vaccine to pregnant women. In this study, we examine data from Israel’s largest healthcare organization to evaluate the effectiveness of the BNT162b2 mRNA vaccine among pregnant women. Methods: We conducted an observational cohort study of pregnant women 16 years or older, with no history of SARS-CoV-2, who were vaccinated between December 20, 2020 and June 3, 2021. Vaccinated subjects were matched to unvaccinated controls according to a set of demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. For each outcome, VE was estimated at several periods following vaccination as one minus the risk ratio using the Kaplan–Meier estimator. Results: 10,861 vaccinated women were matched to an identical number of unvaccinated controls. Estimated VE from 7 through 28 days after the second dose was 97% (95% CI 91%-100%) for any documented infection, 96% (86-100%) for infections with documented symptoms, and 85% (32%-100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group, and no deaths were observed in either group -- insufficient incidence for estimating VE for these outcomes. Discussion: The BNT162b2 mRNA vaccine was found to have high VE among pregnant women. Since high VE has been reported as one of the strongest predictors of COVID-19 vaccine acceptance among pregnant women, the high VE estimates found in this study have the potential to increase vaccine acceptance in this group. In addition, the present VE estimates are similar to those reported in the general population for the same variants, suggesting that it may be possible to infer the VE for pregnant women from studies in the general population for both current and future variants.
9
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
Tom T. Shimabukuro, Shin Y. Kim, Tanya R. Myers et al. · New England Journal of Medicine · 2021 · 955 citations · Full text
Malia Skjefte, Michelle Ngirbabul, Oluwasefunmi Akeju et al. · European Journal of Epidemiology · 2021 · 565 citations · Full text
Veterinary Medicine, Maternal Health, Preventive Medicine +16
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women
Ai‐ris Y. Collier, Katherine McMahan, Jingyou Yu et al. · JAMA · 2021 · 420 citations · Full text